Moreover, recent evidence suggests that the acquisition of resistance to SRC inhibition in BRAF-mutant thyroid cancer cells increases the expression of pro-inflammatory cytokines and pro-invasive metalloproteases, promoting a more invasive phenotype [89]. This evidence concerns the gene SRC and thyroid gland carcinoma.